NASDAQ$TELA
TELA Bio Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
TELA Bio Inc reported Q2 2025 revenue of $20.2 million, up 26% year-over-year, with a net loss of $9.9 million.
TELA Bio Inc delivered Q2 2025 revenue of $20.2 million, driven by 17% growth in OviTex units and 40% growth in OviTex PRS units. Gross margin improved to 70% while operating expenses remained relatively flat, resulting in a reduced net loss of $9.9 million compared to $12.6 million in the prior year quarter. International sales grew to $3.0 million.
- Q2 revenue reached $20.2 million, a 26% increase from $16.1 million in Q2 2024, fueled by higher unit volumes in both OviTex and OviTex PRS portfolios.
- Gross profit rose 27% to $14.1 million with gross margin expanding to 70% due to favorable product mix and lower excess inventory charges.
- Net loss narrowed to $9.9 million from $12.6 million year-over-year as operating expenses grew only 2% despite expanded commercial and R&D activities.
- Cash and cash equivalents stood at $35.0 million at quarter end with total assets of $67.5 million and continued focus on international expansion.
Headline financials
Revenue & EPS history
TELA Bio · Revenue · Quarterly
$20.2M
Revenue by segment
TELA Bio · $7.33M total across 1 segment · Q2 2025
- OviTex PRS$7.33M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-2.5%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+20.2%
Q1 2024
Best reaction
-37.2%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2025 | +1.7% | -9.3% | — | |
| Q1 2026 | -5.3% | -18.6% | -15.7% | |
| Q3 2025 | -9.3% | -2.7% | +3.6% | |
| Q1 2025 | +7.2% | -0.1% | +90.7% | |
| Q4 2024 | -37.2% | -44.9% | -59.1% | |
| Q3 2024 | +2.0% | +3.0% | -1.7% | |
| Q2 2024 | -23.9% | -23.4% | -35.0% | |
| Q1 2024 | +20.2% | +21.2% | +16.7% | |
| Q4 2023 | +4.0% | +0.9% | -13.8% | |
| Q3 2023 | -20.3% | -21.7% | -4.5% | |
| Q2 2023 | -4.8% | -1.2% | -2.8% | |
| Q1 2023 | -3.6% | -4.8% | +11.2% | |
| Q4 2022 | -5.5% | -3.7% | -11.3% | |
| Q3 2022 | +13.8% | +11.2% | +44.7% | |
| Q2 2022 | -6.5% | +5.5% | +0.9% | |
| Q1 2022 | -5.7% | -7.0% | -31.4% | |
| Q4 2021 | -4.8% | -4.8% | -20.4% | |
| Q3 2021 | -3.8% | -3.7% | -1.7% | |
| Q2 2021 | +5.0% | +4.4% | -8.3% | |
| Q1 2021 | +3.2% | +11.5% | +5.9% | |
| Q4 2020 | -6.6% | +0.9% | -1.8% | |
| Q3 2020 | -3.5% | -0.8% | -3.6% | |
| Q2 2020 | +5.4% | +4.1% | +20.7% | |
| Q1 2020 | -2.4% | -3.6% | +38.6% | |
| Q4 2019 | +0.6% | -0.4% | +34.0% | |
| Q3 2019 | +13.9% | +8.8% | +32.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro